These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 15257519)
1. [The efficiency and cost-utility ratio of interferon beta in the treatment of multiple sclerosis in Andalusia]. Medina-Redondo F; Herrera-Carranza J; Sanabria C; Navarro G; García-Moreno JM; Gamero-García MA; Páramo MD; Ruiz-Peña JL; Izquierdo G Rev Neurol; 2004 Jul 1-15; 39(1):1-6. PubMed ID: 15257519 [TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data. Kobelt G; Jönsson L; Miltenburger C; Jönsson B Int J Technol Assess Health Care; 2002; 18(1):127-38. PubMed ID: 11987436 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065 [TBL] [Abstract][Full Text] [Related]
4. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective. Nuijten M; Mittendorf T Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242 [TBL] [Abstract][Full Text] [Related]
5. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Johnson KP; Due DL Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):205-14. PubMed ID: 19527092 [TBL] [Abstract][Full Text] [Related]
6. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson KP Adv Ther; 2009 May; 26(5):552-62. PubMed ID: 19444392 [TBL] [Abstract][Full Text] [Related]
7. [Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain]. Sánchez-De la Rosa R; Sabater E; Casado MA Rev Neurol; 2011 Aug; 53(3):129-38. PubMed ID: 21748710 [TBL] [Abstract][Full Text] [Related]
8. [Cost-utility analisys of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain]. Rubio-Terrés C; Arístegui Ruiz I; Medina Redondo F; Izquierdo Ayuso G Farm Hosp; 2003; 27(3):159-65. PubMed ID: 12835817 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Hernandez L; Guo S; Kinter E; Fay M J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984 [TBL] [Abstract][Full Text] [Related]
10. Glypican 5 is an interferon-beta response gene: a replication study. Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317 [TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E; Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983 [TBL] [Abstract][Full Text] [Related]
12. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Palace J; Duddy M; Bregenzer T; Lawton M; Zhu F; Boggild M; Piske B; Robertson NP; Oger J; Tremlett H; Tilling K; Ben-Shlomo Y; Dobson C Lancet Neurol; 2015 May; 14(5):497-505. PubMed ID: 25841667 [TBL] [Abstract][Full Text] [Related]
14. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Boz C; Oger J; Gibbs E; Grossberg SE; Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study. Darbà J; Kaskens L; Sánchez-de la Rosa R J Med Econ; 2014 Mar; 17(3):215-22. PubMed ID: 24494728 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC Value Health; 2004; 7(5):554-68. PubMed ID: 15367251 [TBL] [Abstract][Full Text] [Related]
18. Lessons from randomised direct comparative trials. Achiron A; Fredrikson S J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860 [TBL] [Abstract][Full Text] [Related]
19. Glatiramer: new preparation. No place in multiple sclerosis. Prescrire Int; 2004 Feb; 13(69):10-2. PubMed ID: 15055208 [TBL] [Abstract][Full Text] [Related]
20. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Río J; Nos C; Tintoré M; Téllez N; Galán I; Pelayo R; Comabella M; Montalban X Ann Neurol; 2006 Feb; 59(2):344-52. PubMed ID: 16437558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]